KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) EBITDA (2016 - 2025)

Medpace Holdings' EBITDA history spans 11 years, with the latest figure at $160.2 million for Q4 2025.

  • For Q4 2025, EBITDA rose 20.88% year-over-year to $160.2 million; the TTM value through Dec 2025 reached $562.1 million, up 18.43%, while the annual FY2025 figure was $562.1 million, 18.43% up from the prior year.
  • EBITDA reached $160.2 million in Q4 2025 per MEDP's latest filing, up from $148.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $160.2 million in Q4 2025 to a low of $46.4 million in Q2 2021.
  • Average EBITDA over 5 years is $95.5 million, with a median of $91.4 million recorded in 2023.
  • Peak YoY movement for EBITDA: increased 0.8% in 2021, then skyrocketed 43.29% in 2022.
  • A 5-year view of EBITDA shows it stood at $59.0 million in 2021, then soared by 38.06% to $81.5 million in 2022, then increased by 14.98% to $93.7 million in 2023, then skyrocketed by 41.41% to $132.5 million in 2024, then increased by 20.88% to $160.2 million in 2025.
  • Per Business Quant, the three most recent readings for MEDP's EBITDA are $160.2 million (Q4 2025), $148.6 million (Q3 2025), and $133.1 million (Q2 2025).